Dr. Zhou Fan (周帆) — Relapsed/Refractory Multiple Myeloma & Metronomic Chemotherapy | Shanghai
In the landscape of multiple myeloma treatment, innovation does not always come from the largest academic centers. Dr. Zhou Fan (周帆), Chief Physician at Shanghai Jing'an District Zhabei Central Hospital, has made a contribution to myeloma treatment that has earned national recognition: his metronomic chemotherapy regimen for relapsed/refractory multiple myeloma has been incorporated into China's national myeloma treatment guidelines — a distinction that places him among a select group of clinicians whose clinical innovations have shaped how myeloma is treated across the country.
Perhaps more importantly for patients: the median survival time of his relapsed/refractory myeloma patients exceeds international benchmarks — a result that speaks directly to the real-world impact of his approach.
Specialty Focus
- Relapsed and refractory multiple myeloma: metronomic chemotherapy and novel combination strategies
- Newly diagnosed multiple myeloma: induction, consolidation, and maintenance planning
- Plasma cell disorders: smoldering myeloma, MGUS, AL amyloidosis
- Myeloma-related complications: bone disease, renal impairment, anemia, infections
- Palliative and quality-of-life-focused myeloma management
Academic & Clinical Titles
- Chief Physician (主任医师), Department of Hematology, Shanghai Jing'an District Zhabei Central Hospital
- 2024 "Shanghai Good Doctor" (上海好医生) Nomination Award recipient
- Author of the metronomic chemotherapy regimen incorporated into the Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma
Metronomic Chemotherapy: A Guideline-Changing Innovation
The term metronomic chemotherapy refers to the administration of chemotherapy at low, continuous doses over extended periods — in contrast to the conventional approach of high-dose chemotherapy given in intermittent cycles with rest periods in between. The rationale is multifaceted: low-dose continuous chemotherapy can suppress tumor angiogenesis, modulate the immune microenvironment, and maintain anti-tumor pressure without the severe toxicity peaks associated with high-dose regimens.
For patients with relapsed/refractory multiple myeloma — who have often already experienced significant cumulative toxicity from prior treatment lines and may have compromised organ function — a metronomic approach offers a potentially more tolerable and sustainable treatment strategy. Dr. Zhou Fan's clinical innovation was to develop and refine a specific metronomic regimen tailored to the biology and clinical characteristics of relapsed/refractory myeloma, and to demonstrate through his clinical practice that this approach can achieve survival outcomes that exceed international benchmarks.
The incorporation of his regimen into China's national myeloma guidelines — the Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma — represents formal recognition by the national hematology community that his approach has sufficient evidence and clinical validity to be recommended for use across Chinese institutions. This is a meaningful distinction: national guidelines are developed by expert committees and reflect a high bar for clinical evidence.
Survival Outcomes That Exceed International Benchmarks
For international patients evaluating treatment options, survival data is the most meaningful metric. Dr. Zhou Fan's relapsed/refractory myeloma patients have achieved median survival times that exceed international benchmarks — a result that reflects not only the efficacy of his metronomic regimen but also his overall approach to myeloma management, including careful patient selection, toxicity monitoring, and supportive care.
It is worth noting that relapsed/refractory myeloma is one of the most challenging clinical situations in hematology. Patients in this category have typically received multiple prior lines of therapy and have disease that has become resistant to standard agents. Achieving survival outcomes that exceed international standards in this population is a clinically significant accomplishment.
The "Shanghai Good Doctor" Recognition
The "Shanghai Good Doctor" (上海好医生) award is a recognition program that identifies physicians who combine clinical excellence with patient-centered care, professional ethics, and community contribution. Dr. Zhou Fan's nomination for this award in 2024 reflects his standing not only as a technically accomplished hematologist but as a physician who is recognized by his peers and patients for the quality and integrity of his practice.
For international patients navigating a complex and emotionally demanding disease like myeloma, the human dimension of medical care matters alongside technical expertise. Dr. Zhou's recognition as a "Good Doctor" speaks to his commitment to patient-centered practice.
A Different Kind of Myeloma Specialist
Dr. Zhou Fan's profile is distinctive in the Shanghai myeloma landscape. While colleagues like Prof. Hou Jian (Renji Hospital), Prof. Liu Peng (Zhongshan Hospital), Prof. Shi Jumei (Oriental Hospital), and Prof. Du Juan (Changzheng Hospital) bring the resources of major academic medical centers, Dr. Zhou's contribution is different: a clinician-innovator whose focused work on a specific clinical problem — how to best treat relapsed/refractory myeloma patients who have exhausted standard options — has produced results that have changed national practice.
For patients who have been told that their options are limited after multiple relapses, Dr. Zhou's metronomic approach may represent a meaningful alternative worth evaluating. CMCS can facilitate a consultation to assess whether his regimen is appropriate for a specific patient's disease profile and prior treatment history.
How CMCS Connects You with Dr. Zhou Fan
China Medical Concierge Shanghai (CMCS) facilitates access to Dr. Zhou Fan for international patients with relapsed/refractory multiple myeloma. Our team manages the full coordination process — from remote case review and medical record translation to appointment scheduling, interpretation, and in-hospital support.
To begin, patients or their families are encouraged to share available medical records including bone marrow biopsy and cytogenetics reports, M-protein quantification (SPEP, UPEP, serum free light chains), imaging studies, organ function assessments, and a complete prior treatment summary including all agents received and responses achieved. Dr. Zhou's team can conduct an initial remote assessment to determine whether his metronomic approach is appropriate for the patient's specific situation.
CMCS provides end-to-end support including:
- Medical record translation (English, Arabic, French, and other languages)
- Remote pre-consultation case review
- Appointment coordination with Dr. Zhou Fan's clinic
- On-site interpretation during consultations
- Post-consultation summary and follow-up support
Contact CMCS to Connect with Dr. Zhou Fan
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician.
0 comments